A. Introduction
The immune status of patients with hematologic disorders, especially various leukemias, may fluctuate according to the clinical course, e.g., acute phase, chronic phase, remission, and smoldering stage. In particular, since leukemia involves a variety of white blood cells, including subsets of lymphocytes, immunologic function as well as general function should be greatly modified, influencing the host defense mechanisms [1] . In this study, nonspecific and specific immune activities of patients with various hematologic disorders were investigated in the different phases of disease.
B. Nonspecific Immune Activity NK activity of peripheral mononuclear cells (PM-NC) against human myeloid K562 cells generally fell in patients with almost all kinds of hematologic disorders and even with solid tumors or chronic infections diseases (Fig. 1) . On the contrary, spontaneous DNA synthesis of PM-NC tends to be elevated in patients with various leukemias, including acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML), and with polycythemia vera, primary myelofibrosis, and primary thrombocythemia ( Fig. 1) . However, PM-NC from patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and solid tumors showed a decrease in spontaneous DNA synthesis. In detail, PM-NC from patients with AML or ALL showed relatively high NK activity, even below the normal range in complete remission, but relatively low levels of spontaneous DNA synthesis in complete remission (Fig. 2) . When PM-NC from patients with leukemias were stimulated with three different mitogens, PHA, SPL (staphage lysate), and Con-A, mitogen-induced DNA synthesis generally fell, except for slight elevation in the complete remission of AML and ALL (Fig. 3) . Particularly, when stimulated with PHA, these PM-NC showed clear elevation in PHA-induced DNA synthesis.
c. Specific Immune Activity
As summarized in Table 1 , one leukemia patient, four lymphoma patients, and two patients with solid tumors were investigated for autochthonous cell-mediated cytotoxicity in comparison with NK activity of their PM-NC against K562 cells. PM-NC from patients with A 11 or Burkitt's malignant lymphomas (patients 1 and 2) did not lyse their own tumor cells by either direct killer T cell-mediated cytotoxicity or antibody-dependent cellular cytotoxicity NK cell activity (% cytolysis) 50 100
Spontaneous DNA synthesis (cpm) Table 2) , but showed significant NK activity. PM-NC from patients 3 and 4 with malignant lymphoma were positive for both ADCC and NK activity. Interestingly, PM-NC from patient 5 with T cell malignant lymphoma were negative for suggest that specific, cytotoxic effector cells selectively penetrated into the malignant tissue, or that, since morphologically these cells are large granular lymphocytes, there may be at least two different NK cell subsets one of which possesses such a specific CMC, but no NK activity and another which possesses NK activity, but no specific CMC [2] . In the light of this specific CMC, the following important observations seem appropriate: (a) tumor cells in different re- 
D. Remarks
The spontaneous DNA synthesis ofPM-NC from most patients with hematologic disorders was higher than the normal level.
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• .. This suggests that PM-NC with normal morphology from these patients may be functionally abnormal like those in the preleukemic stage, since PM-NC from most carriers of human T cell leukemiallymphoma virus type I (H1LV-I) showed increased spontaneous DNA synthesis without malignant transformation [3] . H1LV-I infection may also change the function of PM-NC in H1LV-I carriers [4] . Even though no morphological changes occurred in the PM-NC, DNA synthesis became maximal so that a further increase in DNA synthesis was not induced by mitogen stirn ula tion.
In terms of spontaneous DNA synthesis and NK activity of PM-NC, smoldering AML and CML are quite similar to each other, as described. Accordingly, these two diseases might be considered as one, especially from a nonspecific immunologic point of view [2] . The specificity of cell surface antigens, humoral antibodies, and CMC is very complicated indeed. Thus, diagnosis and treatment of leukemias by immunologic methods are extremely hard to establish. In particular, the immunotherapy of malignancies is not simple, but should be investigated from sophisticated and multiple standpoints.
